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S_umary The measurement of tumour cell proliferation is becoming increasingly recognised in defining
prognostic groups. Proliferating cell nuclear antigen (PCNA) immunolocalisation can be used as an index of
cell proliferation and may define the extent of departure from normal growth control. The monoclonal
antibody PC1O stains PCNA in archival paraffin-embedded tissue. This study investigates its potential as a
prognostic marker in early and advanced ovarian cancer. A three-stage immunoperoxidase technique was
developed to detect the monoclonal antibody PCIO. Archival paraffin-embedded tissue from 19 stage I ovarian
tumours (13 malignant and six borderline) and 79 advanced (stage lIb-IV) ovarian tumours (patients entered
into the Third North-West Thames Ovarian Cancer Trial) was immunostained with PCIO. PCIO immuno-
staining was performed successfully in 91.8% of cases. The PC1O labelling index (PCIO LI) ranged from 1.5%
to 88% with a mean value of 47.4%. Stage I borderline tumours had significantly lower PCNA labelling
indexes than stage I malignant tumours (P<0.048). In advanced disease there was an inverse correlation
between PCIO and overall survival, and in those patients who underwent good debulking surgery (37 patients
with disease <2 cm diameter) a low PCIO value (<36.5%) correlated with improved survival (log-rank trend
test for survival, x = 5.75. P= 0.017). PCNA immunostaining defines a good prognostic subgroup in
adequately debulked patients with ovarian cancer.
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Recent advances in the study of cell cycle control have
suggested the existence of a universal control mechanism
common to all eukaryotic cells, regulating the onset of
mitosis (Nurse, 1992). Normal cellular growth is controlled
by the cell cycle and malignancy arises from derangements of
such proliferation.
The extent to which cells escape from normal cell cycle
control may reflect their degree of malignancy. It is likely
that the association between a high proliferation rate and the
degree of tumour invasiveness is a general feature of human
solid tumours. However, a high proliferation rate is more
likely to be a variable associated with rather than the cause
ofbiological aggressiveness. Departure from normal cell cycle
control may be detectable by measurement of abnormalities
of the expression of antigens associated with cell cycle con-
trol. Such antigens include proliferating cell nuclear antigen
(PCNA).
PCNA is an evolutionarily highly conserved acidic protein
of 36 kDa, which was independently discovered by Miyachi
et al. (1978) as PCNA and by Bravo and Celhs (1980) as
cycin. It has more recently been identified as an essential
accessory factor to the delta polymerase, which is required
for both leading strand DNA replication and DNA repair
(Bravo et al., 1987; Prehlich et al., 1987; Toschi and Bravo,
1988; Shivji et al., 1992). It is necessary for DNA replication,
DNA repair, cell cycle progression, cellular proliferation and
is expressed in late G1-S-phase. PCNA therefore accumu-
lates in cycling cells, and thus in normal tissue PCNA
immunolocalisation can be used as an index of the degree of
cell proliferation as staining is confined to proliferating cells
(Sarraf et al., 1991). In malignant tissue a high level of
PCNA immunostaining may identify aggressive tumours and
provide a guide to the proliferation rate of the tumour (Hall
et al., 1990).
A three-stage immunoperoxidase technique has been used
to detect the monoclonal antibody PCIO raised to genetically
engineered PCNA in archival paraffin-embedded tissue. This
study aimed to determine whether PCIO immunostaining has
a role as a prognostic marker - defining patients with either
aggressive or fast-proliferating tumours. Ovarian cancer was
chosen for study.
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The prognosis of ovarian cancer has remained largely
unchanged in the past decade, since the introduction of
platinum-containing regimens. A few clear prognostic factors
have been defined, such as stage, grade and residual disease
after initial surgery but these are insufficiently discriminating
to either define satisfactorily a good prognostic subgroup or
select those patients to whom it may be appropriate to offer
an additional treatment modality or more intensive treatment
regimens.
Materals and methods
Patients
Earl) stage Pathological specimens from patients with stage
I disease presenting to one consultant (HEL) at Hammer-
smith Hospital between 1983 and 1991 (13 malignant and six
borderline tumours) were studied.
Advanced stage Advanced-disease patients recruited to the
Third North-West Thames Ovarian Cancer Trial between
1985 and 1989 were studied. Archival pathological material
was obtained on 79 patients of the total 271, material being
obtained on all patients presenting to 13 centres of the 43
involved. Treatment consisted initially of five cycles of car-
boplatin. Patients who showed no evidence of progressive
disease then underwent a second-look laparotomy, and res-
ponders were randomised to either a further five cycles of
carboplatin or whole abdominal radiotherapy (Lambert et
al., 1993). The study group is those patients whose tissue was
stained with PC1O and was defined on the basis of intention
to treat, on recruitment to the trial. The 271 patients entered
in the Third North-West Thames Ovarian Cancer Trial are
defined as the whole group.
Histological Classification
The histological samples from diagnostic surgical specimens
obtained at initial laparotomy were used. Sections were
stained with haematoxylin and eosin and graded by one
pathologist, on receipt of the slides from the referring
centres, according to the degree of cellular differentiation
(Decker et al., 1972).H Thomas et a
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PCNA immunostaining
A number ofmonoclonal antibodies to PCNA were raised by
Waseem and Lane (1990), and of 11 with anti-PCNA
specificity six reacted with formalin-fixed material, of
which PC10 had the highest avidity by enzyme-linked
immunosorbent assay (ELISA). PC10 has the advantage of
recognising PCNA in archival material. Formalin-fixed and
paraffin-embedded sections were cut at 4 mm, mounted on
poly-L-lysine-coated glass slides and air dried overnight at
room temperature. Sections were dewaxed, dehydrated with
alcohol and then immersed for 15 min in distilled water with
0.3% hydrogen peroxide to block endogenous peroxidase
activity. Immunostaining was performed using the ABC
method (Dakopatts UK) with a primary incubation for 12 h
at 4°C with PC10 (kindly donated by Professor David Lane,
University of Dundee) at a dilution of 1:20 (cell culture
supernatant). The second layer consisted of biotinylated goat
anti-mouse IgG (Dako, 1:200 dilution) and was applied for
1 h. After rinsing. the final incubation was for 1 h with a
streptavidin-biotin-peroxidase complex (Dakopatts, UK).
Diaminobenzidine-hydrogen peroxide was employed as a
chromogen and a light Cole's haematoxylin counterstain was
used. In negative controls the primary antibody was replaced
with phosphate-buffered saline, while human tonsil acted as
positive controls.
Cell counting
The slides used for PCNA staining and counting were the
consecutive sections after the representative haematoxylin
and eosin histologically examined section. Numbers of sec-
tions available for staining and counting varied from 1-6
(mean 3). All immunostained sections were examined using a
x40 objective with an eyepiece graticule. Tumour cells but
not normal cells were then counted in randomly selected
consecutive high-power fields. PCIO immunostaining was
assessed in 2000 cells and recorded as a percentage. Scoring
of PCIO was carred out without prior knowledge of the
histological grade or clinical stage. A cell was considered
positive if there was any nuclear staining present.
Mitotic index
The mitotic index was measured as the number of mitotic
figures per 2000 tumour cells (%).
PCIO labelling index The PCIO labelling index was defined
as the number of tumour cells with nuclear PCIO immuno-
staining divided by the total number of tumour cells and
expressed as a percentage:
PCIO labelling index = no. of +ve tumour cells 100
(PC1O LI) total no. of cells counted
The PCIO labelling index was taken as an approximate
measure of proliferative fraction. Sarraf et al. (1991) have
shown that, although PC1O overestimates the S-phase frac-
tion, it is a good measure of the growth fraction in many
tissues.
Statistical analssis Overall survival, in months, was cal-
culated from the time of initial presentation until death or
loss to follow-up and was used to generate Kaplan-Meier
log-rank survival curves (Kaplan & Meier, 1958). The data
were divided into tertiles and, using these as ordered
categories, the log-rank trend test was performed. Univariate
analysis of known prognostic factors was performed using
the Mann-Whitney test.
Results
Ninety-eight ovanran tumours were immunostained: six
borderline stage 1, 13 malignant, stage I; 13 stage II, 55 stage
III and 11 stage IV. Nuclear staining was adequate in 91%
of cases and scored positive or negative. Ten cases were
excluded as no staining was visible. This appeared to be due
to technical failure: because of the poor quality of the
archival material heat had to be used to assist adherence of
the section to the glass slide, which resulted in no staining.
PCNA immunostaining is illustrated in Figure la and b.
The characteristics of the study group as compared with the
whole group are outlined in Table I. including the proportion
of patients in the study group and whole group who were
suitable for randomisation and the histological grade and
subgroup.
A lack of concordance was seen between mitotic index and
PCIO LI. The mitotic index ranged from 0.005% to 5%. Cell
cycle times for tumours are thought to be of the order of
8-33 h (Bresciani. 1965; Frankfurt. 1967) and PCNA was
thought to be expressed in S-phase and early G1; a ratio of
PCIO LI to mitotic index of approximately 10-20 might
therefore be expected. The recorded ratios in these patients
ranged from 7 to 330, with 75% of patients having a ratio of
>20. Such a disproportionately high expression of PCNA
may indicate the extent of cell cycle deregulation in those
tumours in which PC10 LI is significantly greater than
mitotic index and may be indicative of a biologically aggres-
sive tumour. Mitotic index relates to grade, and PCIO LI was
found to be independent of grade.
Earl} disease
PCIO LI in early disease ranged from 3.2% to 77.8% with a
mean value of 33.8%. Stage I borderline tumours had
significantly lower PCNA LIs (range 3.2-34.8%. median
23.4%. mean 23.7%) than stage I malignant tumours (range
19.3-77.8%, median 41.5%, mean 42.6%) (P<0.048). Only
one patient with early disease died from the disease - after 58
months, she presented with malignant Stage Ic disease and
had a PCIO LI of 56.9%.
Figme I Photomicrograph illustrating strong nuclear staining in
the majority of cells from a case of ovarian serous cystadenocar-
cinoma (haematoxylin and oesin).PCN4A -i m Nww cancer
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Table I Comparison ofthestudygroup(PCIO) and thewholegroupwith respect
to patient characteristics, residual disease status at initial laparotomy,
randomisation, histological subtype and grades
Study group Whok group
Age and survival
Mean age (years)
Age range (years)
Median survival (months)
Survival range
Stage at initial laparotomy
lib
IIc
III
IV
Histological subtype
Serous
Endometroid
Undifferentiated
Mesonephroid (clear cell)
Mucinous
Mixed mullerian
Mixed serous/mucinous
Not classified
Borderline
Histological grade
I
2
3
Not assessable
Not recorded
53.9
33-73
22
1 day-67 months
6 (8.7%)
4 (5.8%)
50 (72.4%)
9 (13.0%)
35 (51%)
12 (17%)
7 (10%)
5 (7%)
2 (3%)
2 (3%)
1 (1%)
5 (7%)
0 (0%)
4 (6%)
30 (43%)
30 (43%)
5 (7%)
0 (0%)
Residual disease status at initial laparotomy
No residual disease 2 (2.5%)
Disease<2cm at single site 9 (11.4%)
Disease<2 cm at multiple sites 26 (32.9%)
Disease>2cm 35 (44.3%)
Inoperable 7 (8.9%)
Reasons for not randomising
Progressive disease
Refused surgery
Stable disease
Complete response,
no therapy offered
Not assessable at second look
Not eligible for trial
CR. complete response.
28 (75.7%)
2 (5.4%)
2 (5.4%)
3 (8.1%)
2 (5.4%)
8 (5.4%)
52.0
29-73
22
1 day-74 months
13 (4.8%)
0 (3.7%)
212 (78.2%)
36 (13.3%)
38 (51%)
26 (10%)
31 (11%)
13 (5%)
16 (6%)
4 (1%)
2 (1%)
40 (15%)
1 (0.4%)
7 (6%)
79 (29%)
146 (54%)
23 (8%)
6 (22%)
6 (2.2%)
24 (8.9%)
95 (35.0%)
124 (45.8%)
22 (8.1%)
99 (66.9%)
6 (4.0%)
12 (8.1%)
20 (13.5%)
3 (2.0%)
Advanced disease
PCIO LI in advanced disease ranged from 1.5% to 88% with
a mean value of 47.4%. Sixty-nine tumour samples were
stained successfully with the antibody and suitable for
analysis. No selection bias was identified. Of the 16 patients
randomised to receive carboplatin. ten completed ten cycles
of chemotherapy.
On univariate analysis PC1O LI did not correlate with
known prognostic factors: stage, grade or residual disease
(Mann-Whitney P>0.05). The survival by stage of the
PCIO study group is shown in Figure 2. Overall survival for
the study group correlated inversely with PCIO LI (see
Figure 3). Of the 37 patients who underwent good debulking
surgery (<2cm residual disease), 20 were randomised and
received additional therapy (ten to carboplatin and ten to
radiotherapy). Of the remaining 17, five achieved complete
remission, nine suffered disease progression, two had ad-
hesions preventing assessment and one died during chemo-
therapy. In this group a low PCIO value (the lower tertile
was 0-36.5%) correlated with improved survival (see Figure
4) (log-rank trend test for survival, jx = 5.75, P= 0.017).
Survival by PCIO LI for stage 3 well-debulked patients only
is shown in Figure 5 - this excludes the possibility that
unrecognised biological factors have confounded the data.
There were too few events in stage II and IV patients for a
survival curve to have been of value.
Rapid tumour growth rate is generally associated with poor
prognosis (Tubiana and Courdi, 1989). Derangements of cell
cycle control and hence proliferation may result in the
development of malignancy, and the degree of malignancy
may be related to the extent to which cells escape from this
control. Such escape may be detectable by measuring altera-
tion in expression of genes associated with the cell cycle
including p53, Rb and the PCNA gene (De Caprio et al.,
1989; Hall et al., 1990; Levine et al., 1991).
The PCNA gene is necessary for DNA replication, DNA
repair, cell cycle progression and cellular proliferation.
Exposure of cells to antisense oligodeoxynucleotides to
PCNA results in complete cessation of DNA synthesis and
cellular proliferation (Jaskulski et al., 1988; Liu et al., 1989).
Detection of PCNA expression in a cell indicates prolifera-
tion - in normal tissue PCNA staining is confined to pro-
liferating cells. PCNA is expressed in late G,-S-phase, and
several models support the hypothesis that late GI events
play a major role in the control of cell proliferation. When
some GI-arrested, temperature-sensitive mutants of the cell
cycle (Burstin et al., 1974; Talavera and Basilico, 1977) are
induced to overcome the block, they activate a subset of late
GI or GI-S boundary genes (Avanzi et al., 1991).
p53, a nuclear phosphoprotein which controls normal cell
growth, is widely implicated in cell cycle regulation and
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Figure 2 Kaplan-Meier survival curve by stage for study group.
The tick marks show censored observations. For stage II mean
PCIO LI = 35.3%, median PC1O LI = 35.9%, median sur-
vival = 42 months. For stage III mean PCIO LI = 49.2%, median
PC1O LI = 55.8%, median survival = 25 months. For stage IV
mean PC1O LI = 53.7%. median PC1O LI = 59.0%. median sur-
vival = 13 months.
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Figure 3 Log-rank survival curve by PC1O LI for study group.
The tick marks show censored observations. ty,,d = 3.40,
P= 0.065. L = PCIO 0-36.4%, median survival = 42 months.
M = PCIO 36.5-62.5%. median survival = 26 months. H = PCIO
62.6-88.0%. median survival= 23 months.
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Figure 4 Log-rank survival curve by PC1O LI for the good-
surgery subgroup. The tick marks show censored observations.
..d = 5.72, P = 0.017. L = PC1O0 36.4%, median survival=
42 months. M = PCIO 36.5-62.5%, median survival = 17 months.
H = PCIO 62.6-88.0%, median survival = 19 months.
Co
L-
cn
C- co5 ~--- L n = 9
In=7
E E 20-
u
H n = 1 1
10 20 30 40
Time (months)
50 60
Figure 5 Log-rank survival curve by PC1O LI for stage III
patients in the good-surgery subgroup. The tick marks show
censored observations. L = PC10 0-36.4%, median survival = 31
months. M = PCI0 36.5-62.5%, median survival = 26 months.
H = PC1O 62.6-88.0%, median survival = 19 months. These
values do not reach statistical significance as the number of
events in the low- and medium-value groups is too small.
neoplastic transformation; its control may be closely related
to that of the PCNA gene. Conditional expression of wild-
type p53 protein in a cell line (GM47.23) derived from
human glioblastoma multiforme had a negative effect on cell
proliferation (Mercer et al., 1990). It has since been shown in
this cell line that inhibition of cell cycle progression into
S-phase is accompanied by selective down-regulation of
PCNA mRNA and protein expression (Mercer et al., 1991).
Inactivation of the tumour-suppressor activity of p53 appears
to be an almost universal step in the development of human
cancers (Hollstein et al., 1991). In colorectal adenomas its
overexpression has been correlated with increased pro-
liferative rate, as detected by PCNA immunostaining, and
may underlie the dysplasia and loss of proliferative control
characteristic of adenomas with high malignant potential
(Pignatelli et al., 1992). The relationship between p53 and
PCNA has also been demonstrated in prostate carcinoma, in
which again p53 staining has been found to correlate with
PCNA expression (Visakorpi et al., 1992).
Previously measurement of cell proliferation kinetics has
included flow cytometric (FCM) analysis of DNA (S-phase
fraction) or immunohistochemical detection of bromodeox-
yuridine. In ovarian cancer S-phase fraction (SPF) has been
found to be of prognostic significance. A number of studies
of flow cytometric analysis of SPF in epithelial ovarian
cancer have found it a useful and independent prognostic
factor (Vohm et al., 1985; Rutgers et al., 1987; Kallioniemi et
al., 1988; Barnabei et al., 1990). Ovarian tumours of border-
line malignancy (OTBM) have been assessed by means of
flow cytometry as part of larger studies including both
borderline and malignant neoplasms. In most, SPF has been
found to be significantly lower in borderline tumours, in
comparison with malignant epithelial ovarian cancer.
A method of measuring tumour cell proliferation which
can be performed on archival, paraffin-embedded material
has many advantages. Studies on a range of malignancies
have shown that PCNA LI correlates with other means of
measuring tumour proliferation such as flow cytometnrc
analysis of S-phase fraction, tritiated thymidine labelling
index (LI), bromodeoxyuridine (BrdU) identified labelling
index and Ki67 labelling index (Dawson et al., 1990; Alleg-
ranza et al., 1991). In most studies PCNA LI values are
higher than tritated thymidine LI and BrdU LI and S-phase
fractions calculated from flow cytometric DNA histograms
(Garcia et al., 1989). This may, in part, be explained by the
fact that PCNA is expressed during GI, S, G2 and M-phases
of the cell cycle and not just restricted to S-phase.
Comparisons have been made between PCNA immuno-
staining and Ki-67 as a means of assessing proliferative
activity (Louis et al., 1991; van Dierendock et al., 1991). Not
all studies show a correlation between the two methods and a
suggested explanation is that PCNA expression may be
deregulated in malignancy and expressed persistently in some
cells which are not actively dividing (Rosa et al., 1992).
The number of malignancies which have been investigated
with PC1O immunostaining is now very large, and in many
the results have been compared to established prognostic
factors. In gastric carcinoma no correlation was seen between
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tumour stage, histology or presence of lymph node meta-
stases but, examining survival above and below the median
PCIO LI, those with a higher index tended to have a worse
prognosis, though this was not statistically significant (Jain et
al., 1991). In 178 transitional cell bladder cancers (TCCs) the
proportion of PCNA-positive nuclei was related to T status,
N status, WHO histological grade, and predicted progression
in T, N and M categories. The fraction of PCNA-positive
nuclei predicted survival in the entire cohort. In multivariate
analysis of the PCNA LI showed independent predictive
value as a significant prognostic variable in TCC (Lipponen
and Eskelin, 1992). Studies in lymphomas have also demon-
strated that PCNA immunostaining may be of use as a
marker of proliferative activity, with some prognostic
significance (Kamel et al., 1991; Woods et al., 1991). In 194
patients with stage III carcinoma of the cervix treated with
radiation therapy alone a strong correlation was found
between the PC10 index and prognosis, suggesting its poten-
tial as a prognostic indicator in patients with advanced
cancer to be treated with this modality (Oka et al., 1992).
The vast majority of patients with ovarian cancer present
with advanced-stage disease. Adequate debulking surgery is
of prognostic importance and, although the disease is
chemoresponsive, relapse is often inevitable with a 5 year
survival rate in stage III disease of about 20%, virtually
unchanged in the last few decades (American Cancer Society,
1986). This study shows that there is a trend towards high
PC1O values in patients with poor survival and, importantly,
in those patients who had undergone optimal debulking
surgery (<2 cm residual disease), it selects out a subgroup
who have double the median survival (44 as compared with
22 months). This suggests the need for a prospective ran-
domised trial to establish the clinical significance of this
prognostic marker. A knowledge of the proliferative activity
of tumours may be useful in the evaluation of prognosis and
provide a means of selecting patients for appropriate therapy.
Ultimately it may be appropnrate to select patients for more
intensive treatment regimens - for instance maintenance
cytokine therapy or radiolabelled monoclonal antibody
therapy - on the basis of the biology and malignant potential
of disease as determined by quantitation of proliferation,
measured in this way.
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